Organon & Co.
pharmaceutical company
OGN NYSE
ISIN US68622V1061 SEC CIK 1821825 LEI 549300AMCKY57OK2CO56
Follow Organon & Co.
Weekly email: filings, results
Revenue, last quarter
$1.6B
−1.7% vs same quarter last year
Net income
$164M
+2.5% vs same quarter last year
EPS, diluted
$0.60
−1.6% vs same quarter last year
Operating cash flow
$370M
+40.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $6.2B | $187M |
| FY24 | $6.4B | $864M |
| FY23 | $6.3B | $1B |
| FY22 | $6.2B | $917M |
| FY21 | $6.3B | $1.4B |
| FY20 | $6.5B | $2.2B |
| FY19 | $7.8B | $3.2B |
| FY18 | - | - |
- Gross margin
- Net margin
Show the numbers
| Year | Gross margin | Net margin |
|---|---|---|
| FY25 | 53.3% | 3% |
| FY24 | 58% | 13.5% |
| FY23 | 59.8% | 16.3% |
| FY22 | 62.8% | 14.9% |
| FY21 | 62.2% | 21.4% |
| FY20 | 67.6% | 33.1% |
| FY19 | 70.8% | 41.4% |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $538M |
| FY24 | $764M |
| FY23 | $548M |
| FY22 | $662M |
| FY21 | $2B |
| FY20 | $2B |
| FY19 | $2.9B |
| FY18 | - |
Show the numbers
| Year | Dividends |
|---|---|
| FY25 | $88M |
| FY24 | $297M |
| FY23 | $294M |
| FY22 | $290M |
| FY21 | $145M |
| FY20 | $0 |
| FY19 | $0 |
| FY18 | - |
- Organon & Co.
- Healthcare median
Show the numbers
| Year | Organon & Co. | Healthcare median |
|---|---|---|
| FY25 | 3% | −30.6% |
| FY24 | 13.5% | −47% |
| FY23 | 16.3% | −58% |
| FY22 | 14.9% | −80.4% |
| FY21 | 21.4% | −71.9% |
| FY20 | 33.1% | −62.2% |
| FY19 | 41.4% | −46.3% |
| FY18 | - | −49.6% |